Condition: Charcot-Marie-Tooth Disease, Type 1A · Sponsor: Novartis Pharmaceuticals
The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| The Ottawa Hospital | Ottawa, Ontario, Canada | Recruiting |
| Montreal Neurological Institute | Montreal, Quebec, Canada | Recruiting |
| CIUSS de l´Estrie-CHUS- Hôpital Fleurimont | Sherbrooke, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07140614